CTOs on the Move

Atreca

www.atreca.com

 
Atreca is a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics. With its Immune Repertoire Capture™ (IRC™) technology, Atreca has an unparalleled insight into how cancer patients` immune responses can drive better clinical outcomes. Atreca was founded by scientists, industry experts, and investors who share the vision that unlocking the immune response of today`s patients is the key to creating a new generation of therapies. Atreca is looking for talented, entrepreneurial people who are dedicated to making a positive impact on human health.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.atreca.com
  • 500 Saginaw Drive First Floor
    Redwood City, CA USA 94063
  • Phone: 650.595.2595

Executives

Name Title Contact Details

Funding

Atreca raised $56M on 11/04/2015
Atreca raised $35M on 08/17/2017
Atreca raised $125M on 09/12/2018

Similar Companies

Halo Labs

Halo Labs is all about particle analysis. We live to find particles, analyze them, count them, and help our customers characterize them to better their biopharmaceutical products.

Dianthus Therapeutics

Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.

MBL

MBL is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CLONTECH Laboratories

Clontech Laboratories, Inc. develops, produces, and markets innovative biological products to the life science market worldwide. Clontech is a wholly owned subsidiary of Takara Bio, Inc. Learn more about latest Clontech technologies:

PellePharm

We Develop first in class therapies for basal cell carcinomas, including those in gorlin syndrome.